FDA Asks for Input on Reporting Pet Drug Side Effects
Published Date: 2/20/2026
Notice
Summary
The FDA wants your thoughts on how it collects reports about problems with new animal drugs and manufacturing issues. This affects drug makers, vets, and pet owners who help spot side effects in animals. Comments are open until April 21, 2026, so jump in now to help shape safer animal medicines without adding extra costs or delays.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Animal-drug makers: large reporting burden
If you are an applicant or other maker of approved new animal drugs, you must keep records and submit postmarketing adverse event and manufacturing-defect reports under section 512(l) of the FD&C Act and 21 CFR 514.80. FDA lists required forms (FDA Form 1932 and 2301), requires electronic submission of postmarketing safety reports (with limited temporary waivers), and estimates total annual reporting of about 139,561 responses and 194,349.5 hours and total annual recordkeeping of about 124,443 records and 1,742,132 hours (OMB Control Number 0910-0284).
Vets and pet owners: voluntary adverse-event reports
Veterinarians and pet owners can voluntarily report animal adverse events to FDA using FDA Form 1932a; FDA estimates about 217 voluntary public reports per year totaling about 217 hours. These voluntary reports help FDA monitor safety of new animal drugs.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2026-03351 — Development of Guidance for Alternative Fuel Vehicles and Fueling Infrastructure Deployment Under the Clean School Bus Funding Programs
The EPA is gearing up to launch a new funding program to help schools switch to cleaner, alternative fuel buses and build the needed fueling stations. They want your input by April 6, 2026, to make sure the program covers all clean bus technologies and protects taxpayer money from waste or fraud. This means more choices and stronger rules for school districts ready to go green soon!
Next: 2026-03353 — Agency Information Collection Activities; Proposed Collection; Comment Request; New Animal Drugs for Minor Use and Minor Species
The FDA wants your thoughts on how they collect info about new animal drugs for less common animals and uses. This helps make sure these drugs are safe and effective without causing extra paperwork headaches. If you’re involved with these drugs, you’ve got until April 21, 2026, to share your comments—no cost, just your voice!